Reappraisal of Epstein–Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells

Akiko Ohashi, Seiichi Kato, Akinao Okamoto, Yoko Inaguma, Akira Satou, Toyonori Tsuzuki, Nobuhiko Emi, Masataka Okamoto, Shigeo Nakamura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aims: Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) not otherwise specified is defined as monoclonal EBV+ B-cell proliferation affecting patients without any known immunosuppression. Non-neoplastic EBV+ cells proliferating in or adjacent to EBV− DLBCL were reported recently, but their clinical significance is unclear. Thus, the aim of this study was to investigate the prognostic impact of EBV+ cells in DLBCL. Methods and results: We compared the clinicopathological characteristics of 30 EBV+ DLBCL patients and 29 and 604 EBV− DLBCL patients with and without EBV+ bystander cells (median age of onset 71, 67 and 62 years, respectively). Both EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells tended to have high and high–intermediate International Prognostic Index scores (60% and 59%, respectively), as compared with only 46% of EBV− DLBCL patients without EBV+ bystander cells. EBV− DLBCL patients with EBV+ bystander cells showed a significantly higher incidence of lung involvement than those without EBV+ bystander cells (10% versus 2%, P < 0.05). Furthermore, EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells had a poorer prognosis than patients without any detectable EBV+ cells [median overall survival (OS) of 100 months and 40 months versus not reached, P < 0.01]. Notably, EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells treated with rituximab showed overlapping survival curves (OS, P = 0.77; progression-free survival, P = 1.0). Conclusions: EBV− DLBCL with bystander EBV+ cells has similar clinical characteristics to EBV+ DLBCL. DLBCL with EBV+ bystander cells may be related to both age-related and microenvironment-related immunological deterioration.

Original languageEnglish
Pages (from-to)89-97
Number of pages9
JournalHistopathology
Volume71
Issue number1
DOIs
Publication statusPublished - 01-07-2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Viruses
Survival

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Histology

Cite this

Ohashi, Akiko ; Kato, Seiichi ; Okamoto, Akinao ; Inaguma, Yoko ; Satou, Akira ; Tsuzuki, Toyonori ; Emi, Nobuhiko ; Okamoto, Masataka ; Nakamura, Shigeo. / Reappraisal of Epstein–Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL) : comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells. In: Histopathology. 2017 ; Vol. 71, No. 1. pp. 89-97.
@article{970d3954010943d89a239e5072480c7b,
title = "Reappraisal of Epstein–Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL): comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells",
abstract = "Aims: Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) not otherwise specified is defined as monoclonal EBV+ B-cell proliferation affecting patients without any known immunosuppression. Non-neoplastic EBV+ cells proliferating in or adjacent to EBV− DLBCL were reported recently, but their clinical significance is unclear. Thus, the aim of this study was to investigate the prognostic impact of EBV+ cells in DLBCL. Methods and results: We compared the clinicopathological characteristics of 30 EBV+ DLBCL patients and 29 and 604 EBV− DLBCL patients with and without EBV+ bystander cells (median age of onset 71, 67 and 62 years, respectively). Both EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells tended to have high and high–intermediate International Prognostic Index scores (60{\%} and 59{\%}, respectively), as compared with only 46{\%} of EBV− DLBCL patients without EBV+ bystander cells. EBV− DLBCL patients with EBV+ bystander cells showed a significantly higher incidence of lung involvement than those without EBV+ bystander cells (10{\%} versus 2{\%}, P < 0.05). Furthermore, EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells had a poorer prognosis than patients without any detectable EBV+ cells [median overall survival (OS) of 100 months and 40 months versus not reached, P < 0.01]. Notably, EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells treated with rituximab showed overlapping survival curves (OS, P = 0.77; progression-free survival, P = 1.0). Conclusions: EBV− DLBCL with bystander EBV+ cells has similar clinical characteristics to EBV+ DLBCL. DLBCL with EBV+ bystander cells may be related to both age-related and microenvironment-related immunological deterioration.",
author = "Akiko Ohashi and Seiichi Kato and Akinao Okamoto and Yoko Inaguma and Akira Satou and Toyonori Tsuzuki and Nobuhiko Emi and Masataka Okamoto and Shigeo Nakamura",
year = "2017",
month = "7",
day = "1",
doi = "10.1111/his.13197",
language = "English",
volume = "71",
pages = "89--97",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "1",

}

Reappraisal of Epstein–Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL) : comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells. / Ohashi, Akiko; Kato, Seiichi; Okamoto, Akinao; Inaguma, Yoko; Satou, Akira; Tsuzuki, Toyonori; Emi, Nobuhiko; Okamoto, Masataka; Nakamura, Shigeo.

In: Histopathology, Vol. 71, No. 1, 01.07.2017, p. 89-97.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reappraisal of Epstein–Barr virus (EBV) in diffuse large B-cell lymphoma (DLBCL)

T2 - comparative analysis between EBV-positive and EBV-negative DLBCL with EBV-positive bystander cells

AU - Ohashi, Akiko

AU - Kato, Seiichi

AU - Okamoto, Akinao

AU - Inaguma, Yoko

AU - Satou, Akira

AU - Tsuzuki, Toyonori

AU - Emi, Nobuhiko

AU - Okamoto, Masataka

AU - Nakamura, Shigeo

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Aims: Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) not otherwise specified is defined as monoclonal EBV+ B-cell proliferation affecting patients without any known immunosuppression. Non-neoplastic EBV+ cells proliferating in or adjacent to EBV− DLBCL were reported recently, but their clinical significance is unclear. Thus, the aim of this study was to investigate the prognostic impact of EBV+ cells in DLBCL. Methods and results: We compared the clinicopathological characteristics of 30 EBV+ DLBCL patients and 29 and 604 EBV− DLBCL patients with and without EBV+ bystander cells (median age of onset 71, 67 and 62 years, respectively). Both EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells tended to have high and high–intermediate International Prognostic Index scores (60% and 59%, respectively), as compared with only 46% of EBV− DLBCL patients without EBV+ bystander cells. EBV− DLBCL patients with EBV+ bystander cells showed a significantly higher incidence of lung involvement than those without EBV+ bystander cells (10% versus 2%, P < 0.05). Furthermore, EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells had a poorer prognosis than patients without any detectable EBV+ cells [median overall survival (OS) of 100 months and 40 months versus not reached, P < 0.01]. Notably, EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells treated with rituximab showed overlapping survival curves (OS, P = 0.77; progression-free survival, P = 1.0). Conclusions: EBV− DLBCL with bystander EBV+ cells has similar clinical characteristics to EBV+ DLBCL. DLBCL with EBV+ bystander cells may be related to both age-related and microenvironment-related immunological deterioration.

AB - Aims: Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) not otherwise specified is defined as monoclonal EBV+ B-cell proliferation affecting patients without any known immunosuppression. Non-neoplastic EBV+ cells proliferating in or adjacent to EBV− DLBCL were reported recently, but their clinical significance is unclear. Thus, the aim of this study was to investigate the prognostic impact of EBV+ cells in DLBCL. Methods and results: We compared the clinicopathological characteristics of 30 EBV+ DLBCL patients and 29 and 604 EBV− DLBCL patients with and without EBV+ bystander cells (median age of onset 71, 67 and 62 years, respectively). Both EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells tended to have high and high–intermediate International Prognostic Index scores (60% and 59%, respectively), as compared with only 46% of EBV− DLBCL patients without EBV+ bystander cells. EBV− DLBCL patients with EBV+ bystander cells showed a significantly higher incidence of lung involvement than those without EBV+ bystander cells (10% versus 2%, P < 0.05). Furthermore, EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells had a poorer prognosis than patients without any detectable EBV+ cells [median overall survival (OS) of 100 months and 40 months versus not reached, P < 0.01]. Notably, EBV+ DLBCL patients and EBV− DLBCL patients with EBV+ bystander cells treated with rituximab showed overlapping survival curves (OS, P = 0.77; progression-free survival, P = 1.0). Conclusions: EBV− DLBCL with bystander EBV+ cells has similar clinical characteristics to EBV+ DLBCL. DLBCL with EBV+ bystander cells may be related to both age-related and microenvironment-related immunological deterioration.

UR - http://www.scopus.com/inward/record.url?scp=85017604012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017604012&partnerID=8YFLogxK

U2 - 10.1111/his.13197

DO - 10.1111/his.13197

M3 - Article

C2 - 28231401

AN - SCOPUS:85017604012

VL - 71

SP - 89

EP - 97

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 1

ER -